ArticleThe Journal of investigative dermatology2016
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.
Article in The Journal of investigative dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Increased Expression of HLA-DR and CD69 on Peripheral CD4ImmunoTargets and therapy · 2026Article
- Advances in Targeted and Immunotherapy for High-Risk Cutaneous Malignancies.Oncology research · 2026Review
- Antigen-experienced NK-T cells: integrating new insights and exploring therapeutic potential in cancer immunotherapy.Frontiers in immunology · 2026Review
- Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.Oncoimmunology · 2024Article
- An increase in regulatory T cells in peripheral blood correlates with an adverse prognosis for malignant melanoma patients - A study of T cells and natural killer cells.Current research in immunology · 2024Article
- Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.Frontiers in immunology · 2024Review
- Targeting Potential of Innate Lymphoid Cells in Melanoma and Other Cancers.Pharmaceutics · 2023Review
- Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapies.Postepy dermatologii i alergologii · 2022Article
- Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.Frontiers in veterinary science · 2022Article
- Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.Nature immunology · 2021Article
- Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.Frontiers in oncology · 2021Review
- Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.Frontiers in immunology · 2020Review
- The Evolution of Adjuvant Therapy for Melanoma.Current oncology reports · 2019Review
- Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.International journal of molecular sciences · 2019Review
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.Cell research · 2019Article
- Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?Journal for immunotherapy of cancer · 2019Review
- Predictive immune biomarkers: an unattainable chimera?Cellular & molecular immunology · 2018Article
- Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'.Nature communications · 2018Article
- Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers.Frontiers in immunology · 2018Review
- Predictors of responses to immune checkpoint blockade in advanced melanoma.Nature communications · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 3 countries.
Funding
Abstract
Stage III metastatic melanomas require adequate adjuvant immunotherapy to prevent relapses. Prognostic factors are awaited to optimize the clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAF(V600) activating mutation have clinical significance. Based on a comprehensive immunophenotyping of 252 parameters per patient in paired blood and metastatic lymph nodes performed in 39 metastatic melanomas, we found that blood markers were as contributive as tumor-infiltrated lymphocyte immunotypes, and parameters associated with lymphocyte exhaustion/suppression showed higher clinical significance than those related to activation or lineage. High frequencies of CD45RA(+)CD4(+) and CD3(-)CD56(-) tumor-infiltrated lymphocytes appear to be independent prognostic factors of short progression-free survival. High NKG2D expression on CD8(+)tumor-infiltrated lymphocytes, low level of regulatory T-cell tumor-infiltrated lymphocytes, and low PD-L1 expression on circulating T cells were retained in the multivariate Cox analysis model to predict prolonged overall survival. Prospective studies are needed to determine whether such immunological markers may guide adjuvant therapies in stage III metastatic melanomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.